Tedizolid – a new antibiotic to solve old problems: prospects for the treatment of complicated skin and soft tissue infections
Abstract
The work describes a new antibiotic from the oxazolidinone group – tedizolid. The results of the clinical studies have shown a high efficacy of tedizolid in complicated skin and soft tissue infections. The use of tedizolid phosphate was accompanied by high activity against antibiotic-resistant microflora in combination with good tolerability and low frequency of side effects.
About the Authors
A. V. Rodin
Smolensk State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Rodin Anton Viktorovich – Candidate of Medical Sciences, Assistant of the Department of General Surgery witha course of surgery at the Faculty of Additional Professional Education.
214018, Smolensk, 28, Gagarin Avenue; tel: +7 (4812) 61–16–28.
O. I. Agafonov
1409 Naval Clinical Hospital of the Ministry of Defense of the Russian Federation
Russian Federation
Russian Federation
Agafonov Oleg Igorevich – Candidate of Medical Sciences, Head of Surgical Department of the Subdivision No. 2.
238151, Kaliningrad region, Chernyakhovsk, 7, Moskovskaya St.; tel: +7 (911) 856–34–28.
References
1. Surgical skin and soft tissue infections. Russian national recommendations. Edited by B.R. Gelfand et al. M.: MAI Publishing House, 2015, 109 p. (In Russ.)
2. Yamamoto L.G. Treatment of Skin and Soft Tissue Infections. Pediatr Emerg Care. 2017;33 (1):49–55.
3. Bassetti M., Baguneid M., Bouza E., Dryden M., Nathwani D., Wilcox M. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience withlinezolid. Clin Microbiol Infect. 2014;20 (Suppl 4):3–18.
4. Sukhorukova M.V., Skleenova E.Yu., Ivanchik N.V., Timokhova A.V., Eidelstein M.V., Dekhnich A.V. et al. Antibiotic resistance of nosocomial strains of Staphylococcus aureus in Russian hospitals: results of a multi-center epidemiological MARAFON study in 2011–2012. Clinical microbiological antimicrobial chemotherapy [Klin. mikrobiol. antimikrob. himioter.]. 2014;16 (4):280–286. (In Russ.)
5. Loewen K., Schreiber Y., Kirlew M., Bocking N., Kelly L. Community-associated methicillin-resistant Staphylococcus aureus infection: Literature review and clinical update. Can Fam Physician. 2017, 63 (7):512–520.
6. Reshetko O.V., Yakimova Yu.N. Innovative antibiotics for systemic use. Clinical microbiological antimicrobial chemotherapy [Klin. mikrobiol. antimikrob. himioter. 2015;17 (4):272–285.] (In Russ.)
7. Ushkalova E.A. Tedizolid is a new generation of oxazolidinones for treatment of skin and soft tissue infections. Pharmacy [Farmateka]. 2014;15–2:9–12. (In Russ.)
8. Zhanel G.G., Love R., Adam H., Golden A., Zelenitsky S., Schweizer F. et al. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs. 2015;75 (3):253–270.
9. Shaw K.J., Barbachyn M.R. The oxazolidinones: past, present, and future. Ann N Y Acad Sci. 2011;1241:48–70.
10. Bae S.K., Yang S.H., Shin K.N., Rhee J.K., Yoo M., Lee M.G. Pharmacokinetics of DA-7218, a new oxazolidinone, and its active metabolite, DA-7157, after intravenous and oral administration of DA-7218 and DA-7157 to rats. J Pharm Pharmacol. 2007;59 (7):955–963.
11. Rybak J.M., Roberts K. Tedizolid phosphate: a next-generation oxazolidinone. Infect Dis Ther. 2015;4:1–14.
12. Locke J.B., Zurenko G.E., Shaw K.J., Bartizal K. Tedizolid for the man¬agement of human infections: in vitro characteristics. Clin Infect Dis. 2014;58 (Suppl 1):S35-S42.
13. Ferrández O., Urbina O., Grau S. Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections. Drug Des Devel Ther. 2017;11:65–82.
14. Colca J.R., McDonald W. G., Waldon D.J. et al. Cross-linking in theliving celllocates the site of action of oxazolidinone antibiotics. J Biol Chem. 2003;278 (24):21972–21979.
15. Kanafani Z.A., Corey G.R. Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Expert Opin Investig Drugs. 2012;21 (4):515–522.
16. Wilson D.N., Schluenzen F., Harms J.M., Starosta A.L., Connell S.R., Fucini P. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc Natl Acad Sci U S A. 2008;105 (36):13339–13344.
17. Leach K.L., Swaney S.M., Colca J.R., McDonald W. G., Blinn J.R., Thomasco L.M. et al. The site of action of oxazoli¬dinone antibiotics inliving bacteria and in human mitochondria. Mol Cell. 2007;26 (3):393–402.
18. Flanagan S.D., Bien P.A., Munoz K.A., Minassian S.L., Prokocimer P.G. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacotherapy. 2014;34 (3):240–250.
19. Ong V., Flanagan S., Fang E., Dreskin H.J., Locke J.B., Bartizal K. et al. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos. 2014;42 (8):1275–1284.
20. Housman S.T., Pope J.S., Russomanno J. et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother. 2012;56 (5):2627–2634.
21. Chen R., Shen K., Chang X., Tanaka T., Li L., Hu P. Pharmacokinetics and Safety of Tedizolid after Single and Multiple Intravenous/Oral Sequential Administrations in Healthy Chinese Subjects. Clin Ther. 2016;38 (8):1869–1879.
22. Sahm D.F., Deane J., Bien P.A., Locke J.B., Zuill D.E., Shaw K.J. еt al. Results of the Surveillance of Tedizolid Activity and Resistance Program: in vitro susceptibility of Gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagnostic Microbiology and Infectious Disease. 2015;81 (2):112–118.
23. Prokocimer P., Bien P., Surber J., Mehra P., DeAnda C., Bulitta J.B. et al. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother. 2011;55 (2):583–592.
24. Prokocimer P., De Anda C., Fang E., Mehra P., Das A. Tedizolid phosphate vslinezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013;309 (6):559–569.
25. Moran G.J., Fang E., Corey G.R., Das A.F., De Anda C., Prokocimer P. Tedizolid for 6 days versuslinezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14 (8):696–705.
26. Shorr A.F., Lodise T.P., Corey G.R., De Anda C., Fang E., Das A.F. et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015;59 (2):864–871.
27. Bel’kova Yu.A., Rachina S.A., Kozlov R.S., Golub A.V., Portnyagina U.S., Shamaeva S.H. Perspectives of tedizolid inclusion in the form of the Russian multi-profile hospital for the treatment of complicated skin and soft tissues infections. Clinical microbiological antimicrobial chemotherapy [Klin. mikrobiol. antimikrob. himioter. 2016;18 (3):174–185.] (In Russ.)
Review
For citations:
Rodin A.V., Agafonov O.I. Tedizolid – a new antibiotic to solve old problems: prospects for the treatment of complicated skin and soft tissue infections. Ambulatornaya khirurgiya = Ambulatory Surgery (Russia). 2019;(1-2):80-86. (In Russ.)
Views:
10544
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International.
Email this article 